FDA-Approved GLP-1 Medications (2026)
Eleven GLP-1 and dual GIP/GLP-1 receptor agonists are currently FDA-approved in the United States. This list covers every one, organized by primary FDA-approved indication — chronic weight management or type 2 diabetes — with approval dates, dosing, and efficacy for each. Some drugs carry secondary FDA indications such as cardiovascular risk reduction, obstructive sleep apnea, or adolescent use; those appear as badges on each drug.
FDA-approved for chronic weight management
4 drugs
Foundayo
NEWIngredient: orforglipronCompany: Eli LillyOral, once daily12.4% mean weight lossApproved Apr 2026
Zepbound
OSAIngredient: tirzepatideCompany: Eli LillyInjection, once weekly22.5% mean weight lossApproved Nov 2023
Wegovy
CV riskAges 12+Ingredient: semaglutideCompany: Novo NordiskInjection, once weekly16.9% mean weight lossApproved Jun 2021
Saxenda
Ages 12+Ingredient: liraglutideCompany: Novo NordiskInjection, once daily8% mean weight lossApproved Dec 2014
FDA-approved for type 2 diabetes
7 drugs
Mounjaro
Ingredient: tirzepatideCompany: Eli LillyInjection, once weeklyA1C -2.4 ptsApproved May 2022
Rybelsus
Ingredient: semaglutideCompany: Novo NordiskOral, once dailyA1C -1.4 ptsApproved Sep 2019
Ozempic
CV riskIngredient: semaglutideCompany: Novo NordiskInjection, once weeklyA1C -1.8 ptsApproved Dec 2017
Trulicity
CV riskIngredient: dulaglutideCompany: Eli LillyInjection, once weeklyA1C -1.5 ptsApproved Sep 2014
Bydureon BCise
Ingredient: exenatide extended-releaseCompany: AstraZenecaInjection, once weeklyA1C -1.3 ptsApproved Jan 2012
Victoza
CV riskIngredient: liraglutideCompany: Novo NordiskInjection, once dailyA1C -1.1 ptsApproved Jan 2010
Byetta
Ingredient: exenatideCompany: AstraZenecaInjection, twice daily (within 60 min before meals)A1C -0.8 ptsApproved Apr 2005